Abbott Laboratories: shareholders and insiders

ABTNYSEHealthcare · Pharmaceutical Preparations

Price

$104.48

November 18, 2026Market cap $182B

What Ploutos Investor adds for Abbott Laboratories

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 17 fiscal years, from 2009
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Insiders and their shares

Purchases and sales by officers and directors from Nov 19, 2025 to Nov 6, 2026, from their own Form 4 filings.

19 Form 4s

Bought on the market

$4.4M

4 people

Sold on the market

$48M

7 people

From Nov 19, 2025 to Nov 19, 2026, the days the chart shows. Change its range and the figures follow.

How the sales were made, as a share of their value

  • Under a set plan0%
  • The rest100%

By year

Insiders' open-market purchases (up) and sales (down), by value, since Nov 19, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.

2026·bought $4.4M by 4 people·sold $48M by 7 people

  • 2025: no buys, sold $203.0K by 1 person
  • 2026: bought $4.4M by 4 people, sold $48M by 7 people
  • Nov 5, 2026Mary K MorelandEXECUTIVE VICE PRESIDENT
    Kind
  • Sep 23, 2026Kevin T ConroyDirector
    Kind
  • Sep 2, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER
    Kind
  • Sep 1, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER
    Kind
  • Sep 1, 2026Philip P BoudreauEVP AND CFO
    Kind
  • Aug 25, 2026Robert B FordCHAIRMAN AND CEO
    Kind
  • Aug 25, 2026Robert B FordCHAIRMAN AND CEO
    Kind
  • Aug 25, 2026Robert B FordCHAIRMAN AND CEO
    Kind
  • Aug 25, 2026Robert B FordCHAIRMAN AND CEO
    Kind
  • Aug 12, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENT
    Kind
  • Aug 11, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENT
    Kind
  • Jun 30, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENT
    Kind
  • Jun 27, 2026Elizabeth C. CushmanEVP, GC AND SECRETARY
    Kind
  • May 7, 2026John G StrattonDirector
    Kind
  • Apr 27, 2026Daniel J Starks
    Kind
  • Apr 23, 2026Philip P BoudreauEVP AND CFO
    Kind
  • Mar 2, 2026Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT
    Kind
  • Mar 2, 2026John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER
    Kind
  • Mar 2, 2026Mary K MorelandEXECUTIVE VICE PRESIDENT
    Kind
  • Mar 2, 2026Louis H. MorroneEXECUTIVE VICE PRESIDENT
    Kind
  • Mar 2, 2026Eric ShroffSenior Vice President
    Kind
  • Mar 2, 2026Elizabeth C. CushmanEVP, GC AND SECRETARY
    Kind
  • Feb 4, 2026Daniel J Starks
    Kind
  • Feb 4, 2026Daniel J Starks
    Kind
  • Jan 23, 2026Robert B FordCHAIRMAN AND CEO
    Kind

From the Form 4s insiders file with the SEC within two business days of each trade. Before Jun 18, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.

Insiders and their shares

Every buy and sale by ABT's officers and directors from 2006 up to November 18, 2025, 20 more calendar years

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 3 years.

Major holders (over 5%)

Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.

1 Holders over 5%Apr 29, 2026 Latest filing
  • Vanguard Capital Management
    Share of class7.50%
Fell to 5% or less (1)

Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.

  • The Vanguard Group0.00%Mar 26, 202613G/A

From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.

Well-known managers

Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.

Sep 30, 2026 quarter end
  • Southeastern Asset Mgmt
    In the quarter
  • Citadel Advisors (Griffin)
    In the quarter+349%
  • Point72 (Cohen)
    In the quarter
  • Millennium Mgmt (Englander)
    In the quarter+172%
  • AQR Capital
    In the quarter+167%
  • D.E. Shaw
    In the quarter-72%
  • Renaissance Technologies
    In the quarter-33%
  • Bridgewater (Dalio)
    In the quarter-49%

From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).

Short interest

How many of the company's shares have been sold borrowed and not yet bought back, twice a month.

On Oct 15, 2026, 1.00% of its shares outstanding were held short, +27.5% since the report before.

Shares held short
17.39M
1.00%
Since the report before13.63M on Sep 30, 2026
+27.5%
1.8
9.77M
More days to cover thanof 4,578 US-listed companies with enough volume
22%
Report date
Oct 15, 2026
  • Oct 31, 2023: Shares held short 9.88M
  • Nov 15, 2023: Shares held short 12.08M
  • Nov 30, 2023: Shares held short 11.75M
  • Dec 15, 2023: Shares held short 12.31M
  • Dec 29, 2023: Shares held short 11.88M
  • Jan 12, 2024: Shares held short 10.55M
  • Jan 31, 2024: Shares held short 12.70M
  • Feb 15, 2024: Shares held short 14.29M
  • Feb 29, 2024: Shares held short 14.92M
  • Mar 15, 2024: Shares held short 15.72M
  • Mar 28, 2024: Shares held short 14.48M
  • Apr 15, 2024: Shares held short 12.94M
  • Apr 30, 2024: Shares held short 14.48M
  • May 15, 2024: Shares held short 14.77M
  • May 31, 2024: Shares held short 14.50M
  • Jun 14, 2024: Shares held short 11.62M
  • Jun 28, 2024: Shares held short 13.00M
  • Jul 15, 2024: Shares held short 10.75M
  • Jul 31, 2024: Shares held short 13.63M
  • Aug 15, 2024: Shares held short 12.68M
  • Aug 30, 2024: Shares held short 12.75M
  • Sep 13, 2024: Shares held short 13.36M
  • Sep 30, 2024: Shares held short 11.83M
  • Oct 15, 2024: Shares held short 13.98M
  • Oct 31, 2024: Shares held short 14.07M
  • Nov 15, 2024: Shares held short 12.05M
  • Nov 29, 2024: Shares held short 13.57M
  • Dec 13, 2024: Shares held short 12.10M
  • Dec 31, 2024: Shares held short 14.32M
  • Jan 15, 2025: Shares held short 14.97M
  • Jan 31, 2025: Shares held short 18.24M
  • Feb 14, 2025: Shares held short 22.31M
  • Feb 28, 2025: Shares held short 22.93M
  • Mar 14, 2025: Shares held short 21.88M
  • Mar 31, 2025: Shares held short 21.79M
  • Apr 15, 2025: Shares held short 21.69M
  • Apr 30, 2025: Shares held short 21.12M
  • May 15, 2025: Shares held short 22.26M
  • May 30, 2025: Shares held short 20.09M
  • Jun 13, 2025: Shares held short 20.80M
  • Jun 30, 2025: Shares held short 19.43M
  • Jul 15, 2025: Shares held short 19.06M
  • Jul 31, 2025: Shares held short 18.33M
  • Aug 15, 2025: Shares held short 17.11M
  • Aug 29, 2025: Shares held short 17.75M
  • Sep 15, 2025: Shares held short 18.07M
  • Sep 30, 2025: Shares held short 18.17M
  • Oct 15, 2025: Shares held short 19.36M
  • Oct 31, 2025: Shares held short 20.17M
  • Nov 14, 2025: Shares held short 19.14M
  • Nov 28, 2025: Shares held short 18.49M
  • Dec 15, 2025: Shares held short 15.88M
  • Dec 31, 2025: Shares held short 17.40M
  • Jan 15, 2026: Shares held short 19.91M
  • Jan 30, 2026: Shares held short 18.73M
  • Feb 13, 2026: Shares held short 17.20M
  • Feb 27, 2026: Shares held short 18.23M
  • Mar 13, 2026: Shares held short 19.95M
  • Mar 31, 2026: Shares held short 23.83M
  • Apr 15, 2026: Shares held short 21.75M
  • Apr 30, 2026: Shares held short 22.54M
  • May 15, 2026: Shares held short 23.22M
  • May 29, 2026: Shares held short 22.04M
  • Jun 15, 2026: Shares held short 21.97M
  • Jun 30, 2026: Shares held short 23.39M
  • Jul 15, 2026: Shares held short 24.85M
  • Jul 31, 2026: Shares held short 22.62M
  • Aug 14, 2026: Shares held short 20.38M
  • Aug 31, 2026: Shares held short 22.13M
  • Sep 15, 2026: Shares held short 19.91M
  • Sep 30, 2026: Shares held short 13.63M
  • Oct 15, 2026: Shares held short 17.39M

As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.

Short sales in daily trading36.1% of the shares in the last 14 sessions' reported trades were short sales.

In the last 14 sessions, 36.1% of the shares in the reported trades were short sales, against 43.0% in the 14 before.

Last 14 sessionsOct 30, 2026 – Nov 18, 2026
36.1%
The 14 beforeOct 12, 2026 – Oct 29, 2026
43.0%
Change
-6.9 pts
Short sales a dayon average, of 3.01M shares
1.08M
More than atof 3,656 US-listed companies, same days
12%
Median of alleight in ten from 34.4% to 63.7%
50.3%
  • Oct 12, 2026: Short sales 43%
  • Oct 13, 2026: Short sales 34.7%
  • Oct 14, 2026: Short sales 40.1%
  • Oct 15, 2026: Short sales 40.3%
  • Oct 16, 2026: Short sales 34.8%
  • Oct 19, 2026: Short sales 27.9%
  • Oct 20, 2026: Short sales 54%
  • Oct 21, 2026: Short sales 50.3%
  • Oct 22, 2026: Short sales 48.4%
  • Oct 23, 2026: Short sales 36.5%
  • Oct 26, 2026: Short sales 51%
  • Oct 27, 2026: Short sales 52.6%
  • Oct 28, 2026: Short sales 43%
  • Oct 29, 2026: Short sales 31.5%
  • Oct 30, 2026: Short sales 59.7%
  • Nov 2, 2026: Short sales 56.8%
  • Nov 3, 2026: Short sales 34.6%
  • Nov 4, 2026: Short sales 37.8%
  • Nov 5, 2026: Short sales 38.2%
  • Nov 6, 2026: Short sales 33.8%
  • Nov 9, 2026: Short sales 34.8%
  • Nov 10, 2026: Short sales 31.5%
  • Nov 11, 2026: Short sales 38.1%
  • Nov 12, 2026: Short sales 17.9%
  • Nov 13, 2026: Short sales 25.9%
  • Nov 16, 2026: Short sales 24.1%
  • Nov 17, 2026: Short sales 26.2%
  • Nov 18, 2026: Short sales 32.6%

This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.

What the insiders hold

The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.

8.47M Insiders' shares0.49% Of the company
  • Daniel J StarksDirector
    Directly6.75M
  • Robert B FordCHAIRMAN AND CEO
    Directly306.5K
  • Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
    Directly211.3K
  • Hubert L AllenEXECUTIVE VICE PRESIDENT
    Directly184.8K
  • Daniel Gesua Sive SalvadoriEVP AND GROUP PRESIDENT
    Directly146.4K
  • Mary K MorelandEXECUTIVE VICE PRESIDENT
    Directly118.1K
  • Philip P BoudreauEVP AND CFO
    Directly80.1K
  • Kevin T ConroyDirector
    Directly81.2K
  • Andrea F WainerRETIRED EVP
    Directly74.4K
  • Lisa D EarnhardtEVP AND GROUP PRESIDENT
    Directly71.9K
  • Louis H. MorroneEXECUTIVE VICE PRESIDENT
    Directly70.7K
  • Eric ShroffSenior Vice President
    Directly39.2K
  • Elizabeth C. CushmanEVP, GC AND SECRETARY
    Directly38.0K
  • Sally E. BlountDirector
    Directly34.1K
  • John A. Mccoy Jr.VICE PRESIDENT AND CONTROLLER
    Directly24.5K
  • John G StrattonDirector
    Directly23.3K

A lower bound: it counts only the 16 officers and directors with a market trade since Nov 20, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.

10b5-1 trading plans

Since 2023 every 10-Q and 10-K says which insiders adopted or ended a trading plan (Rule 10b5-1) in the quarter: when, for how many shares, until when. A plan explains the sales that follow months before they show up on Form 4.

0 Adopted in the last 12 months15 Filings read
  • Hubert L. AllenExecutive Vice President, General Counsel and Secretary
    What happenedAdoptedMay 10, 2024
    Shares157.4K
  • Robert E. Funck, Jr.Executive Vice President, Finance
    What happenedAdoptedMay 10, 2024
    Shares45.0K
  • Andrea F. WainerExecutive Vice President, Rapid and Molecular Diagnostics
    What happenedAdoptedMay 1, 2023
    Shares–

As the company states them in Item 9B of the 10-K and Part II, Item 5 of the 10-Q, with structured data. A plan allows sales on preset dates and prices. It does not say whether all of them will be executed.

Executive pay

From the Pay versus Performance table every company puts in its proxy statement since 2023: what the chief executive was paid, what was actually paid once the shares vest at year-end values, and how the stock did against the peer group the company itself picked.

2025 Latest year6 Years on record

$24M

Actually paid: $27M

$7.5M

Actually paid: $7.6M

–

Adjusted Diluted EPS

From the proxy statement (DEF 14A) of Mar 13, 2026, as filed with the SEC with structured data. Pay in dollars. The company picks its own peer group and measure. DEF 14A

Share repurchases

How many of its own shares the company bought each quarter, at what average price, for how much, and what remains of the program its board authorized, from the table it puts in every 10-Q and 10-K.

$2.0B Repurchases over 4 quarters$5.6B Left in the program
  • Jun 30, 202610-Q
    Amount$1.0B
  • Dec 31, 202510-K
    Amount$301M
  • Sep 30, 202510-Q
    Amount$303M
  • Dec 31, 202410-K
    Amount$366M
  • Sep 30, 202410-Q
    Amount$750M
  • Dec 31, 202310-K
    Amount$300M
  • Jun 30, 202310-Q
    Amount$425M
  • Dec 31, 202210-K
    Amount$682M

From the "Issuer Purchases of Equity Securities" table of the 10-Qs and 10-Ks, read without a model. Only the quarters whose shares times average price agree with the cash the company says it paid for repurchases in its cash-flow statement are shown. The shares include those withheld for officers' taxes. A quarter with an accelerated repurchase shows the table's shares and the cash paid, without an average price. 8 filing(s) not shown, as the table was not read or did not agree with the cash.

The shareholders' vote on pay

The advisory say-on-pay vote at each annual meeting, as the company states it in the 8-K it files after the meeting: how many voted for and against the executives' pay. 90% is the norm. Under 70% proxy advisers expect the board to respond the next year.

90.7% For in 20266 Votes on record
  • 2026Apr 27, 2026
    For
    90.7%
  • 2025Apr 28, 2025
    For
    90.4%
  • 2024Apr 29, 2024
    For
    89.4%
  • 2023May 2, 2023
    For
    90.5%
  • 2022May 2, 2022
    For
    91.8%
  • 2021Apr 26, 2021
    For
    92.4%

From the 8-K (item 5.07) the company files after each annual meeting since 2021, read from the filing's text without a model. A company that votes every three years has empty years. The vote is advisory: the board is not bound by it. 1 filing(s) not read, as the table is not in the usual shape.

The ETFs that hold it

Which of the 345 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.

62 ETFs holding it16.93% The largest weight (IHI)
  • IHIiShares U.S. Medical Devices ETF
    Weight in the fund16.93%
  • SCHDSchwab U.S. Dividend Equity ETF
    Weight in the fund4.68%
  • IYHiShares U.S. Healthcare ETF
    Weight in the fund3.02%
  • XLVState Street(R) Health Care Select Sector SPDR(R) ETF
    Weight in the fund2.75%
  • VHTVanguard Health Care Index Fund
    Weight in the fund2.66%
  • QLTYGMO U.S. Quality ETF
    Weight in the fund2.57%
  • HDViShares Core High Dividend ETF
    Weight in the fund2.29%
  • IXJiShares Global Healthcare ETF
    Weight in the fund2.05%
  • NOBLProShares S&P 500 Dividend Aristocrats ETF
    Weight in the fund1.55%
  • DGROiShares Core Dividend Growth ETF
    Weight in the fund1.10%

62 of the 345 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.

Institutional investors by quarter

Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.

2,970 Managers, Q2 2026$125B Value of their positions
  • Q3 2025: Managers 3,183
  • Q4 2025: Managers 3,295
  • Q1 2026: Managers 3,121
  • Q2 2026: Managers 2,970

Institutional investors by quarter

The fund managers holding ABT, quarter by quarter, from Q1 2013 to Q2 2025, 50 more quarters

Part of Ploutos Investor, €9.99 a month

See the plans

Sign in with a free account to see the last 12 quarters.

Q2 2026: 2,970 managers held 1.38B shares, worth $125B. During the quarter 190 opened a position, 341 closed one, 1,027 added and 1,364 trimmed.

The largest holders, Q2 2026

  • BlackRock
    In the quarter+4.7%
  • Vanguard Capital Management
    In the quarter+0.7%
  • State Street
    In the quarter+1.7%
  • Charles Schwab Investment Management
    In the quarter+31%
  • Vanguard Portfolio Management
    In the quarter+2.2%
  • Geode Capital Management
    In the quarter+0.2%
  • Capital Research Global Investors
    In the quarter-26%
  • Capital International Investors
    In the quarter-7.6%
  • Morgan Stanley
    In the quarter-12%
  • Norges Bank
    In the quarter-0.4%

From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.

The full analysis

What do Abbott Laboratories's filings show?

Who buys and sells is one part of Abbott Laboratories's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

Questions about ABT's shareholders

Didn't find what you were looking for?

Ask us
Have ABT's insiders bought or sold?

From Jun 18, 2026 to Nov 6, 2026 Abbott Laboratories's insiders bought $173.6K and sold $47M of shares on the market. 0% of the sales were under set 10b5-1 plans.

Which well-known managers hold ABT?

8 of the managers we track held the shares on Sep 30, 2026. The largest position was Citadel Advisors (Griffin)'s, worth $780M.

Is every insider transaction a purchase or a sale?

No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.